Increased incidence of thrombotic microangiopathy after ABO-incompatible living donor liver transplantation

Norihiro Kishida, Masahiro Shinoda, Osamu Itano, Hideaki Obara, Minoru Kitago, Taizo Hibi, Hiroshi Yagi, Yuta Abe, Kentaro Matsubara, Masanori Odaira, Minoru Tanabe, Motohide Shimazu, Yuukou Kitagawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Thrombotic microangiopathy (TMA) is a severe life-threatening complication associated with solid organ trans-plantation. We retrospectively investigated the incidence, risk factors, and appropriate treatment of TMA following adult living donor liver transplantation (LDLT). Material/Methods: The subjects were 129 adult patients who underwent LDLT in our department from 1997 to 2014. Patients with TMA were identified retrospectively based on diagnostic criteria. We calculated the incidence of TMA and performed a risk factor analysis for TMA occurrence. We also assessed our past treatments for TMA and sought to identify the most appropriate form of treatment. Results: Thirteen patients were identified as having TMA. The incidence of TMA in the study cohort was 10.1% but was especially high (37.9%) among ABO-incompatible cases. A univariate analysis revealed that ABO incompatibility, usage of tacrolimus, usage of rituximab, and cold ischemic time ≥50 minutes are risk factors for occurrence of TMA (p<0.10). Multivariate analysis demonstrated that ABO incompatibility was the only independent risk factor for TMA (p=0.009). Initiation of treatment on the day of TMA diagnosis was associated with better survival. Conclusions: ABO incompatibility is an independent risk factor for TMA following adult LDLT. Our results suggest that early initiation of treatment is crucial for improving the outcomes.

Original languageEnglish
Pages (from-to)755-764
Number of pages10
JournalAnnals of Transplantation
Volume21
DOIs
Publication statusPublished - 2016 Dec 13

Fingerprint

Thrombotic Microangiopathies
Living Donors
Liver Transplantation
Incidence
Therapeutics
Cold Ischemia
Tacrolimus
Statistical Factor Analysis

Keywords

  • Liver transplantation
  • Living donors
  • Plasma exchange
  • Thrombotic microangiopathies

ASJC Scopus subject areas

  • Transplantation

Cite this

Increased incidence of thrombotic microangiopathy after ABO-incompatible living donor liver transplantation. / Kishida, Norihiro; Shinoda, Masahiro; Itano, Osamu; Obara, Hideaki; Kitago, Minoru; Hibi, Taizo; Yagi, Hiroshi; Abe, Yuta; Matsubara, Kentaro; Odaira, Masanori; Tanabe, Minoru; Shimazu, Motohide; Kitagawa, Yuukou.

In: Annals of Transplantation, Vol. 21, 13.12.2016, p. 755-764.

Research output: Contribution to journalArticle

@article{29043881a022459980c4cb0223284f32,
title = "Increased incidence of thrombotic microangiopathy after ABO-incompatible living donor liver transplantation",
abstract = "Background: Thrombotic microangiopathy (TMA) is a severe life-threatening complication associated with solid organ trans-plantation. We retrospectively investigated the incidence, risk factors, and appropriate treatment of TMA following adult living donor liver transplantation (LDLT). Material/Methods: The subjects were 129 adult patients who underwent LDLT in our department from 1997 to 2014. Patients with TMA were identified retrospectively based on diagnostic criteria. We calculated the incidence of TMA and performed a risk factor analysis for TMA occurrence. We also assessed our past treatments for TMA and sought to identify the most appropriate form of treatment. Results: Thirteen patients were identified as having TMA. The incidence of TMA in the study cohort was 10.1{\%} but was especially high (37.9{\%}) among ABO-incompatible cases. A univariate analysis revealed that ABO incompatibility, usage of tacrolimus, usage of rituximab, and cold ischemic time ≥50 minutes are risk factors for occurrence of TMA (p<0.10). Multivariate analysis demonstrated that ABO incompatibility was the only independent risk factor for TMA (p=0.009). Initiation of treatment on the day of TMA diagnosis was associated with better survival. Conclusions: ABO incompatibility is an independent risk factor for TMA following adult LDLT. Our results suggest that early initiation of treatment is crucial for improving the outcomes.",
keywords = "Liver transplantation, Living donors, Plasma exchange, Thrombotic microangiopathies",
author = "Norihiro Kishida and Masahiro Shinoda and Osamu Itano and Hideaki Obara and Minoru Kitago and Taizo Hibi and Hiroshi Yagi and Yuta Abe and Kentaro Matsubara and Masanori Odaira and Minoru Tanabe and Motohide Shimazu and Yuukou Kitagawa",
year = "2016",
month = "12",
day = "13",
doi = "10.12659/AOT.900915",
language = "English",
volume = "21",
pages = "755--764",
journal = "Annals of Transplantation",
issn = "1425-9524",
publisher = "International Scientific Information, Inc.",

}

TY - JOUR

T1 - Increased incidence of thrombotic microangiopathy after ABO-incompatible living donor liver transplantation

AU - Kishida, Norihiro

AU - Shinoda, Masahiro

AU - Itano, Osamu

AU - Obara, Hideaki

AU - Kitago, Minoru

AU - Hibi, Taizo

AU - Yagi, Hiroshi

AU - Abe, Yuta

AU - Matsubara, Kentaro

AU - Odaira, Masanori

AU - Tanabe, Minoru

AU - Shimazu, Motohide

AU - Kitagawa, Yuukou

PY - 2016/12/13

Y1 - 2016/12/13

N2 - Background: Thrombotic microangiopathy (TMA) is a severe life-threatening complication associated with solid organ trans-plantation. We retrospectively investigated the incidence, risk factors, and appropriate treatment of TMA following adult living donor liver transplantation (LDLT). Material/Methods: The subjects were 129 adult patients who underwent LDLT in our department from 1997 to 2014. Patients with TMA were identified retrospectively based on diagnostic criteria. We calculated the incidence of TMA and performed a risk factor analysis for TMA occurrence. We also assessed our past treatments for TMA and sought to identify the most appropriate form of treatment. Results: Thirteen patients were identified as having TMA. The incidence of TMA in the study cohort was 10.1% but was especially high (37.9%) among ABO-incompatible cases. A univariate analysis revealed that ABO incompatibility, usage of tacrolimus, usage of rituximab, and cold ischemic time ≥50 minutes are risk factors for occurrence of TMA (p<0.10). Multivariate analysis demonstrated that ABO incompatibility was the only independent risk factor for TMA (p=0.009). Initiation of treatment on the day of TMA diagnosis was associated with better survival. Conclusions: ABO incompatibility is an independent risk factor for TMA following adult LDLT. Our results suggest that early initiation of treatment is crucial for improving the outcomes.

AB - Background: Thrombotic microangiopathy (TMA) is a severe life-threatening complication associated with solid organ trans-plantation. We retrospectively investigated the incidence, risk factors, and appropriate treatment of TMA following adult living donor liver transplantation (LDLT). Material/Methods: The subjects were 129 adult patients who underwent LDLT in our department from 1997 to 2014. Patients with TMA were identified retrospectively based on diagnostic criteria. We calculated the incidence of TMA and performed a risk factor analysis for TMA occurrence. We also assessed our past treatments for TMA and sought to identify the most appropriate form of treatment. Results: Thirteen patients were identified as having TMA. The incidence of TMA in the study cohort was 10.1% but was especially high (37.9%) among ABO-incompatible cases. A univariate analysis revealed that ABO incompatibility, usage of tacrolimus, usage of rituximab, and cold ischemic time ≥50 minutes are risk factors for occurrence of TMA (p<0.10). Multivariate analysis demonstrated that ABO incompatibility was the only independent risk factor for TMA (p=0.009). Initiation of treatment on the day of TMA diagnosis was associated with better survival. Conclusions: ABO incompatibility is an independent risk factor for TMA following adult LDLT. Our results suggest that early initiation of treatment is crucial for improving the outcomes.

KW - Liver transplantation

KW - Living donors

KW - Plasma exchange

KW - Thrombotic microangiopathies

UR - http://www.scopus.com/inward/record.url?scp=85006915411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006915411&partnerID=8YFLogxK

U2 - 10.12659/AOT.900915

DO - 10.12659/AOT.900915

M3 - Article

C2 - 27956735

AN - SCOPUS:85006915411

VL - 21

SP - 755

EP - 764

JO - Annals of Transplantation

JF - Annals of Transplantation

SN - 1425-9524

ER -